Literature DB >> 22045173

The role of lymph node dissection in renal cell carcinoma.

Scott E Delacroix1, Brian F Chapin, Christopher G Wood.   

Abstract

The role of lymph node dissection (LND) in the staging and treatment of renal cell carcinoma has long been a topic of debate. The controversy has focused on whether LND is purely an adjunctive staging procedure or has a therapeutic role in the management of this disease. Potential benefits include enhanced staging, better selection for adjuvant therapies/clinical trials, a decrease in recurrence rates, and improved disease-specific and overall survival. This article reviews the available literature on LND in renal cell carcinoma and discusses the potential benefits of aggressive surgical resection in select high-risk patients. Copyright Â
© 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22045173     DOI: 10.1016/j.ucl.2011.07.008

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  3 in total

1.  Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience.

Authors:  Wassim M Bazzi; Daniel D Sjoberg; Michael A Feuerstein; Alexandra Maschino; Sweeney Verma; Melanie Bernstein; Matthew F O'Brien; Thomas Jang; William Lowrance; Robert J Motzer; Paul Russo
Journal:  J Urol       Date:  2014-12-15       Impact factor: 7.450

Review 2.  The role of open radical nephrectomy in contemporary management of renal cell carcinoma.

Authors:  Arveen A Kalapara; Mark Frydenberg
Journal:  Transl Androl Urol       Date:  2020-12

3.  Diagnostic and Prognostic Significance of Radiologic Node-positive Renal Cell Carcinoma in the Absence of Distant Metastases: A Retrospective Analysis of Patients Undergoing Nephrectomy and Lymph Node Dissection.

Authors:  Hye Won Lee; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hyun Moo Lee
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.